Cancer procoagulant
From Infogalactic: the planetary knowledge core
| Cancer procoagulant | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Identifiers | |||||||||
| EC number | 3.4.22.26 | ||||||||
| CAS number | Template:CAS | ||||||||
| Databases | |||||||||
| IntEnz | IntEnz view | ||||||||
| BRENDA | BRENDA entry | ||||||||
| ExPASy | NiceZyme view | ||||||||
| KEGG | KEGG entry | ||||||||
| MetaCyc | metabolic pathway | ||||||||
| PRIAM | profile | ||||||||
| PDB structures | RCSB PDB PDBe PDBsum | ||||||||
|
|||||||||
Cancer procoagulant is a hypothesised protein, most likely a cysteine protease enzyme (EC 3.4.22.26), that occurs only in fetal and malignant cells. Its activity appears to be the activation of factor X, one of the coagulation factors, and would account for the increased incidence of thrombosis in cancer patients. Tissue factor (TF) is also known to be present at increased levels around malignant cells.
References
- De Cicco M. The prothrombotic state in cancer: pathogenic mechanisms. Crit Rev Oncol Hematol 2004;50:187-96. PMID 15182825.
External links
- cancer procoagulant at the US National Library of Medicine Medical Subject Headings (MeSH)
